Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT03072238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).
Study identification
- NCT ID
- NCT03072238
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,101 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2017 (Actual)
- Primary completion
- Mar 16, 2020 (Actual)
- Completion
- Apr 24, 2024 (Actual)
- Last update posted
- Jun 6, 2025
2017 – 2024
United States locations
- U.S. sites
- 32
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers | Chandler | Arizona | 85224 | — |
| Mayo Clinic Arizona | Scottsdale | Arizona | 85025 | — |
| City of Hope | Duarte | California | 91010 | — |
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| Stanford University | Palo Alto | California | 94305 | — |
| Pacific Hematology Oncology Associates | San Francisco | California | 94115 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Lynn Cancer Institute/Boca Raton Regional Hospital | Boca Raton | Florida | 33486 | — |
| Miami Cancer Institute of Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Associates in Oncology/Hematology P.C. | Rockville | Maryland | 20850 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute.. | Detroit | Michigan | 48201 | — |
| HCA Midwest Division | Kansas City | Missouri | 64132 | — |
| Urology Cancer Center & GU Research Network | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley | Las Vegas | Nevada | 89169 | — |
| Hackensack Univ Medical Center | Hackensack | New Jersey | 07601 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Northwest Cancer Specialists, P.C. | Tualatin | Oregon | 97062 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Allegheny Cancer Center | Pittsburgh | Pennsylvania | 15212 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Charleston Oncology, P .A | Charleston | South Carolina | 29414 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| Texas Oncology - Gulf Coast | The Woodlands | Texas | 77380 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84132-0001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03072238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2025 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03072238 live on ClinicalTrials.gov.